SLCO1B1和ABCG2基因型信息化表型与拉米普里尔暴露的变化有关
Houwaida Abbes1,2,3, Pablo Zubiaur1, Paula Soria-Chacartegui1
1Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Basic & clinical pharmacology & toxicology
|July 16, 2024
概括
在SLCO1B1和ABCG2的遗传变异显著影响身体如何处理拉米普利尔,影响药物暴露. 这种药物遗传学的洞察力对于个性化的高血压和心力衰竭治疗至关重要.
科学领域:
- 药物基因组学 药物基因组学
- 药物代谢和运输 药物代谢和运输
- 心血管药理学心血管药理学
背景情况:
- 拉米普利是ACE抑制剂,广泛用于高血压和心力衰竭.
- 关于影响拉米普利尔疗效和安全性的遗传因素的研究有限.
- 了解药物遗传学关联可以优化拉米普里尔治疗.
研究的目的:
- 为了研究120个基因变异在34个药物基因对拉米的药理动力学的影响.
- 确定遗传变异与拉米普利尔药物不良反应发生率之间的关联.
- 为了确定影响拉米普里尔暴露变异性的关键基因.
主要方法:
- 从拉米普里尔生物等效临床试验中招募了29名健康志愿者.
- 在34个药物基因 (CYPs,UGTs,ABC,SLC载体) 中分析了120个遗传变异.
- 进行了单变体和多变体分析,以将基因型与拉米的药理动力学 (AUC/DW) 相对应.
主要成果:
- SLCO1B1和ABCG2基因型知情的表型显著预测了拉米普里尔的暴露.
- 具有SLCO1B1功能下降 (DF) 现型的个体显示拉米普利尔AUC/DW.约1.7倍高.
- 具有ABCG2 DF+差功能 (PF) 现型的个体显示拉米普利尔AUC/DW ~ 1.6倍高.
结论:
- SLCO1B1和ABCG2是影响拉米的药理动力学的关键转运体.
- 这些载体中的遗传变异显著改变了拉米普里尔的暴露.
- 需要进一步的研究来证实个人化拉米普利尔剂量的临床相关性.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
Antihypertensive Drugs: Angiotensin II Receptor Blockers
695
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
695
Structure-Activity Relationships and Drug Design
697
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
697
Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K


